Expanded access trials in Puerto Rico

Showing 1 to 13 of 13. Each trial links to its page on Pharma Observatory.

• Atazanavir for HIV Infected Individuals: An Early Access Program NCT00046345·Expanded access·No longer available·Bristol-Myers Squibb·Started 2002
• An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection NCT00162227·Expanded access·No longer available·Bristol-Myers Squibb·Started 2000
• A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation NCT00149981·Expanded access·No longer available·Novartis Pharmaceuticals
• TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens. NCT00245739·Expanded access·Approved for marketing·Tibotec Pharmaceuticals, Ireland
• The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs NCT00354627·Expanded access·Approved for marketing·Tibotec Pharmaceuticals, Ireland
• Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection NCT00499720·Expanded access·Approved for marketing·Gilead Sciences
• Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer NCT01217697·Expanded access·Approved for marketing·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
• An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma NCT01833039·Expanded access·Approved for marketing·Janssen Biotech, Inc.
• BMN 110 US Expanded Access Program NCT01858103·Expanded access·Approved for marketing·BioMarin Pharmaceutical
• Expanded Access: Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI NCT04513821·Expanded access·Available·Leonard-Meron Biosciences, Inc.
• An Intermediate Size Expanded Access Protocol of AMX0035 for ALS NCT05286372·Expanded access·Approved for marketing·Amylyx Pharmaceuticals Inc.
• A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2) NCT06069934·Expanded access·No longer available·Prilenia
• Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma NCT07573215·Expanded access·Approved for marketing·Revolution Medicines, Inc.